GlassScriptPhysician profile
Trent H Smith
NPI 1336110576
$9,471.30
in general payments reported to CMS, 2019-2025
24 companies · $217 in 2025
The $217 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,444 · 2020: $1,259 · 2021: $2,229 · 2022: $2,356 · 2023: $664 · 2024: $302 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,146 · Education: $36.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.45 |
| Education | $36.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,160.82 | 2019-2025 | Enbrel, Tavneos, Avsola |
| Abbvie INC. | $1,257.41 | 2019-2023 | Rinvoq, Humira |
| Pfizer INC. | $1,042.37 | 2019-2025 | |
| Ucb, INC. | $620.14 | 2019-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $421.32 | 2019-2024 | Taltz, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $349.54 | 2019-2021 | |
| Janssen Biotech, INC. | $285.26 | 2019-2023 | Tremfya, Simponi Aria, Remicade |
| Glaxosmithkline, LLC. | $245.63 | 2019-2023 | Benlysta |
| Novartis Pharmaceuticals Corporation | $232.22 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.53 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $219.59 | 2020-2023 | Uptravi, Opsumit |
| Mallinckrodt Enterprises LLC | $193.72 | 2019 | |
| Celgene Corporation | $178.55 | 2019 | |
| Aurinia Pharma U.S., INC. | $172.03 | 2021-2022 | |
| Sobi, INC | $118.23 | 2019-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $116.96 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $104.42 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $104.14 | 2021 | |
| Horizon Therapeutics Plc | $101.76 | 2019-2022 | |
| Genentech USA, INC. | $94.43 | 2019-2020 | |
| Genzyme Corporation | $87.29 | 2019-2020 | |
| Radius Health, INC. | $79.50 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $29.44 | 2019-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $28.00 | 2022-2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trent Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.